Different Serum, Different Protein Corona! The Impact of the Serum Source on Cellular Targeting of Folic Acid-Modified Chitosan-Based Nanoparticles

The nanoparticle (NP) protein corona represents an interface between biological components and NPs, dictating their cellular interaction and biological fate. To assess the success of cellular targeting, NPs modified with targeting ligands are incubated with target cells in serum-free culture medium...

Full description

Saved in:
Bibliographic Details
Published in:Molecular pharmaceutics 2022-05, Vol.19 (5), p.1635-1646
Main Authors: Ezzat, Aya A, Tammam, Salma N, Hanafi, Rasha S, Rashad, Omar, Osama, Aya, Abdelnaby, Eman, Magdeldin, Sameh, Mansour, Samar
Format: Article
Language:English
Subjects:
Breast Neoplasms - drug therapy
Chitosan
Female
Folic Acid
Humans
Nanoparticles - metabolism
Protein Corona - metabolism
Proteomics
Reproducibility of Results
Serum Albumin, Bovine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The nanoparticle (NP) protein corona represents an interface between biological components and NPs, dictating their cellular interaction and biological fate. To assess the success of cellular targeting, NPs modified with targeting ligands are incubated with target cells in serum-free culture medium or in the presence of fetal bovine serum (FBS). In the former, the role of the corona is overlooked, and in the latter, the effects of a corona that does not represent the one forming in humans nor the respective disease state are considered. Via proteomic analysis, we demonstrate how the difference in the composition of FBS, sera from healthy human volunteers, and breast cancer patients (BrCr Pt) results in the formation of completely different protein coronas around the same NP. Successful in vitro targeting of breast cancer cells was only observed when NPs were incubated with target cells in the presence of BrCr Pt sera only. In such cases, the success of targeting was not attributed to the targeting ligand itself, but to the adsorption of specific serum proteins that facilitate NP uptake by cancer cells in the presence of BrCr Pt sera. This work therefore demonstrates how the serum source affects the reliability of in vitro experiments assessing NP–cell interactions and the consequent success or failure of active targeting and may in fact indicate an additional reason for the limited clinical success of drug targeting by NPs in cancer.
ISSN:1543-8384
1543-8392
DOI:10.1021/acs.molpharmaceut.2c00108